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Self-reported sleep disturbance in 
Crohn’s disease is not confirmed by 
objective sleep measures
Heba n. iskandar1,6*, Emily E. Linan2,6, Ami patel3, Renee Moore4, Yi Lasanajak4, 
c. prakash Gyawali2, Gregory S. Sayuk2,5 & Matthew A. ciorba2*
Sleep disturbance and fatigue are commonly reported among patients with Crohn’s disease (CD). In 
this prospective study, we aimed to define sleep quality in CD patients at various disease activity states 
and compare to healthy controls using objective and subjective measures. A prospective observational 
cohort study of CD patients seen at a tertiary academic inflammatory bowel diseases (IBD) clinic was 
compared to healthy volunteers. CD activity was assessed using the Harvey-Bradshaw Index (HBI). 
Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness 
Scale (ESS) and objectively over 1-week using actigraphy (motion-based) and morning urinary 
melatonin metabolite. 121 subjects (CD patients N = 61; controls N = 60) completed the study. 34 
had active CD (HBI > 4). Sleep disturbance was more frequently reported by CD subjects than controls 
(PSQI: 57% vs. 35%, p = 0.02) and in patients with active CD versus in remission state (PSQI 75.8% vs. 
33.3%, p < 0.01; ESS: 45.5% vs. 19%, p = 0.03). Sleep parameters as measured by actigraphy and urine 
melatonin metabolite did not vary by group. Crohn’s patients report significantly more disturbed sleep 
than controls. However, poor sleep was not confirmed by objective measures of sleep quality. Excessive 
daytime sleepiness in CD patients may be driven by factors beyond objectively measured poor sleep.
Crohn’s disease (CD) is one of the two major types of chronic inflammatory bowel disease (IBD) that together 
affect nearly 5 million individuals worldwide1. Fatigue is a common symptom associated with CD, particularly in 
patients with active disease. While the cause of fatigue can be multifactorial, sleep quality is considered a likely 
contributing factor2.
Several studies link inflammatory bowel disease, and CD in particular, with sleep disturbance and daytime 
sleepiness as well as fatigue2–5. The literature suggests a bidirectional dynamic to the cause-effect relationship 
of these disorders. Questionnaire-based studies have found that patients with active CD are more likely to have 
sleep disturbance than those in remission2,5,6. Alternatively, other questionnaire based studies indicate that sleep 
disturbance itself may place CD patients at increased risk of disease flares7,8. Animal studies confirm the latter by 
demonstrating that circadian disruption worsens colitis severity in experimental models9. This existing literature 
highlights the importance of this health issue; however most studies to date are limited by small patient cohorts 
or lack of objective sleep quality assessments or healthy controls for comparison.
To assess the relationship between CD and sleep we conducted a prospective cohort study examining both 
subjective and objective measures of sleep disturbance. Using these tools, we sought to determine whether CD 
diagnosis alone was associated with sleep disturbance and whether disease activity influenced sleep quality. 
Additionally, we examined a urinary metabolite of melatonin to determine if melatonin deficiency may exist as a 
plausible biological link between sleep disturbance and CD activity.
Materials and Methods
Study design and patient selection. We conducted a prospective cohort study examining sleep qual-
ity in CD patients and healthy controls. Eligibility criteria included patients with age range from 18–50 years. 
Crohn’s disease patients must have had an IBD specializing gastroenterologist confirm the CD diagnosis and 
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been seen a minimum of two clinic visits. An age cutoff of 50 years was used to limit variability in sleep quality 
linked with aging10. Exclusion criteria for both CD and control subjects included factors that could impact sleep 
quality which were: functional GI disorders11, sleep apnea, BMI > 35, major medical illness (cardiopulmonary 
disorders, cirrhosis, or significant chronic renal disease or active malignancy), night-shift workers, smokers and 
heavy drinkers, and patients taking sedating medications (analgesics, muscle relaxants, antineoplastic agents, 
phenytoin, amphetamines, prescription weight-loss drugs, or benzodiazepines, thyroid medication, and anticho-
linergic/antihistamine medications)12.
CD patients were recruited from an outpatient gastroenterology clinic at Washington University School of 
Medicine in St. Louis. The medical charts of the CD patients were pre-screened to determine eligibility. Controls 
were recruited through a university-sponsored program supporting patient-oriented research (https://vfh.wustl.
edu/). Eligibility for controls was initially assessed via a phone-based prescreen questionnaire that listed the 
exclusion criteria. Our hypothesis was that sleep disturbance is greater in CD patients than controls. Our aim was 
to recruit 60 subjects in both cohorts based on an assumed effect size of 0.51, using the actigraphy results from our 
IBS study (IBS: 63 +/− 43, Control: 98 +/− 90), an alpha level of 0.05, and a power of 80%11. We needed a sample 
size of 60 IBD patients and 60 controls for a final power of 80.1% to reject the null hypothesis.
Patient assessments. All study participants completed comprehensive survey-based assessments and 
objective measurements of sleep quality at time of consent and/or while wearing the actigraph. The schedule of 
testing is detailed in Table 1. Demographics and relevant social history (smoking status, alcohol use, occupation, 
education level, housing and income) were also recorded. A list of complete comorbid illnesses for included sub-
jects is included as Supplementary Table 1.
Subjective assessments of sleep quality. Sleep quality was assessed using validated questionnaire-based 
assessments. Participants filled out the Pittsburgh Sleep Quality Index (PSQI) at the time of consent and actigra-
phy13. This questionnaire yields a global score and six component sub-scores related to subjective sleep quality, 
sleep latency, sleep duration, sleep efficiency, daytime sleepiness, sleep medications and sleep disturbances, as well 
as a global sleep score. Additionally, patients completed the Epworth Sleepiness Scale (ESS) at the time of consent 
and actigraphy14. ESS measures daytime sleepiness and the likelihood of falling asleep in eight different settings. 
All subjects completed sleep questions that were adapted from the National Sleep Foundation Daily Sleep Log 
(sleepfoundation.org/sleep-diary/SleepDiaryv6.pdf). Questions captured subjects subjective sleep quality. The 
sleep log allowed patients to record any information that may affect their sleep quality (napping habits, exercise, 
caffeine use, medication, GI daily symptoms and other environmental factors).
Objective measures of sleep quality. Participants wore a motion logger actigraph (Ambulatory 
Monitoring, Inc. Ardsley, NY) continuously for a 7-day period. An actigraph is a watch like devices that records 
sleep patterns and circadian rhythms equivalent to a polysomnogram (PSG)15,16. Advantages of actigraphy as an 
objective measure of sleep quality include the ability to measure sleep quality in the patient’s natural environment 
for extended period of time17. The stored digital information from the actigraph was downloaded and analyzed 
using software (ActionW version 2.7.3045). Actigraphy data yielded total sleep time, latency to persistent sleep, 
sleep onset latency, total wake time during sleep, numbers of wake episodes, longest sleep episode duration, mean 
sleep episodes, and total sleep time (Supplementary Table 2). Actigraphy data was manually compared to the 
subject’s daily log by a single investigator trained by an experienced user and the software technicians to verify 
accuracy of the actigraphy software and identify any patient errors in use.
CD activity. Assessment of clinical disease activity was performed in the clinic upon enrollment and at the 
end of the study period using the Harvey Bradshaw index (HBI)18. CD patients were grouped for dichotomous 
analysis with an HBI score of ≥5 considered to be active CD and those ≤4 as in remission19. Medications, disease 
severity and location of disease was based on the Montreal Classification were assessed by their physician at time 
of consent20.
Tests and procedures
Time of Consent Time of Actigraphy
Healthy 
Controls CD
Healthy controls CD
Day 1 2 3 4 5 6 7 Day 1 2 3 4 5 6 7
Prescreened for eligibility x x
Demographics and social history x x
Pittsburgh Sleep Quality Index x x x x
Epworth Sleepiness Scale x x x x
Hospital Anxiety and Depression Scale x x x x
Short Inflammatory Bowel Disease Questionnaire x x
Short-form health survey x x x x
Harvey Bradshaw index x x
National Sleep Foundation Daily Sleep Log x x x x x x x x x x x x x x
Actigraphy x x x x x x x x x x x x x x
Urine sample x x
Table 1. Subjective and objective measures that were completed at time of consent and actigraphy.
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Quality of life measures. Three validated survey tools were used to assess subject quality of life. The Short 
Inflammatory Bowel Disease Questionnaire (SIBDQ) evaluates four domains of functioning: bowel symptoms, 
systemic symptoms, emotional symptoms and social factors21. For a generalized measure of comparison between 
control and CD patients, the Short-form 36 (SF-36) was used. The SF-36 is a validated assessment of health related 
quality of life which normalized to a maximum score of 100 with higher scores reflecting greater quality-of-life22. 
The Hospital Anxiety and Depression Scale (HADS) measures depression and anxiety with sub-scores classified 
as abnormal with a score ≥823,24.
Urine metabolite. The urinary 6-hydroxymelatonin sulfate/creatinine ratio (aMT6s:Cr ratio) correlates with 
nighttime circulating melatonin levels24. This biomarker is used as a surrogate biomarker in sleep studies exam-
ining outpatients not available for blood draws at awakening25,26. In this study, urine was collected in the early 
morning as the first morning void and refrigerated. Urine samples were sent via overnight FedEx (preaddressed 
and stamped) with a frozen icepack. Levels were previously demonstrated to be stable after overnight shipping 
for 24–48 hours24. Immediately upon receipt, samples were aliquoted and frozen at −80 °C for batched analysis 
by enzyme-linked immunoabsorbance assay (ELISA) (Genway Labs, SD, USA). The test results were normalized 
using creatinine concentration and expressed as nanograms of aMT6s per mg creatinine. Testing was performed 
as part of the scientific core service of the Yerkes Regional Primate Center biochemistry core at Emory University.
Statistical analysis. Demographic, social, clinical characteristics, survey sleep measures and quality of life 
measures are reported utilizing mean (SD) for continuous variables and frequency (percentage) for categorical 
variables. The characteristics were compared in two different ways: 1) CD patients versus Control and 2) CD 
patients in remission versus those with active disease. For each of these comparisons, we compared means (medi-
ans) utilizing the independent two-sample t-test (or nonparametric Wilcoxon Rank-Sum test, as appropriate for 
non-normal distributions). We compared proportions utilizing Chi-square tests or the non-parametric Fisher’s 
exact tests. The aforementioned tests were also utilized to examine differences in Actigraphy measures between 
CD patients in remission and active CD patients. Multivariate logistic regression modeling was used to iden-
tify predictors of poor sleep (PSQI > 5). From the logistic regression model Odds Ratio (OR) and p-values are 
reported. Generalized linear regression and logistic regression were used to assess mediation27. Tests of hypothe-
ses were two-sided, and a significance level of 0.05 was used throughout. All data analyses were performed using 
the statistical software package, SAS version 9.4
ethical considerations. The Human Research Protection Office (institutional review board) at Washington 
University School of Medicine approved this study and all subjects underwent the informed consent process. 
Our study was performed in accordance with all relevant guidelines and regulations. Our primary study data is 
available upon request.
Results
patient characteristics. Medical records were pre-screened for eligibility criteria. A total of 178 CD patients 
were approached for enrollment during their physician visit. Of the 178 CD patients approached, 35 patients 
refused, 17 were ineligible for the study and 65 patients failed to follow-up with the study coordinator. A total of 
110 Volunteer for Health participants contacted our study coordinator to serve as controls. 20 subjects were found 
ineligible by phone screen and 30 were lost to follow-up. A total of 121 subjects (CD patients N = 61; controls 
N = 60) completed the study. Of the CD patients, 34 were considered to have active disease (HBI > 4) during 
study participation. Participant demographics are listed in Table 2. Compared to the control cohort, enrolled CD 
patients were more likely to be of Caucasian race, married and carry current health insurance. Some CD patients 
listed a diagnosis of IBS that was given prior to CD diagnosis and this was not considered an exclusion criterion. 
Two patients, one CD patient and one control were diagnosed with a sleep disorder after enrollment. There were 
no significant differences in demographics between patients with CD in remission or active disease.
Subjective measures of sleep. Subjective assessments of sleep and quality of life scores are provided in 
Table 3. By PSQI questionnaires, CD patients were significantly more likely to have disturbed sleep than controls 
(57% vs 35%, p = 0.02). This effect was driven by patients with active CD. In subgroup analysis, sleep disturbance 
was significantly more pronounced in patients with active CD (HBI > 4) than in patients with CD in remission 
(75.8% poor sleep in the active CD group vs. only 33.3% in patients in remission, p < 0.01). This effect also held 
true in the ESS (45.5% poor sleep in active CD vs. 19% in CD in remission, p = 0.03). Not surprisingly, patients 
with active CD had a poorer quality of life, as measured by SIBDQ and SF-36.
We characterized predictors of poor sleep in the Crohn’s patients as measured by PSQI using a multivariable 
logistic regression model (Table 4). We also addressed confounders of CD activity as a variable predicting poor 
sleep. Significant predictors of poor sleep included active CD (OR 3.6, p = 0.03), anxiety (OR 1.3, p < 0.01), and 
higher BMI (OR 1.2, p = 0.01). A higher urine melatonin level approached significance as a predictor associated 
with poor sleep (OR 1.01, p = 0.05). This model is adjusted for IBS diagnosis, anti-TNF therapy, antidepressant 
use, depression using HADS score, SIBDQ, number of bowel movements, and sleep onset latency. Number of 
bowel movements interrupting sleep was included as a potential confounder. Even though study participants in 
the CD group have significantly more bowel movements (Table 3), this variable was not significant in our multi-
variable logistic regression model.
Objective measures of sleep. The subjective questionnaires results were in contrast with the objective 
actigraphy data. Actigraphy data showed no significant differences in sleep measures including total sleep time, 
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sleep onset latency, sleep efficiency, and total waking time during sleep, between control and CD patients or 
between CD in remission compared with active CD (Table 5).
Urine melatonin was not significantly different between study groups, and there was no significant correlation 
between melatonin and disease activity (p = 0.09 for active CD vs the other 2 groups, and p = 0.14 across the 3 
groups). Hence, the magnitude of the effect of urine melatonin on sleep quality decreases when adjusting for CD 
activity (Fig. 1).
Demographic and social 
characteristics
Control group 
(n = 60)
Crohn’s disease 
(n = 61) P
Crohn’s disease/ 
Active (n = 34)
Crohn’s disease/
remission (n = 27) P
Median Age (years) 32 31.5
0.56
31.1 34.4
0.11
White 42 (71.2%) 53 (88.3%) 23 (85.2%) 30 (90.9%)
Black 14 (23.7%) 7 (11.7%) 4 (14.8%) 3 (9.1%)
Other 3 (5.1%) 0 0 0
Relationship status
0.02 0.16
Never married 32 (53.3%) 26 (42.6%) 15 (55.6%) 11 (32.4%)
Married 16 (26.7%) 30 (49.2%) 11 (40.7%) 19 (55.9%)
Divorced, separated or widowed 12 (20.0%) 5 (8.2%) 1 (3.7%) 4 (11.8%)
Education
0.93 0.96
High school or less 8 (13.3%) 7 (11.5%) 3 (11.1%) 4 (11.8%)
Some college 19 (31.7%) 19 (31.2%) 9 (33.3%) 10 (29.4%)
College degree 23 (38.3%) 22 (36.1%) 10 (37%) 12 (35.3%)
Graduate degree 10 (16.7%) 13 (21.3%) 5 (18.5%) 8 (23.5%)
Family income
0.77 0.46
<$20,000 10 (16.7%) 7 (12.1%) 3 (12%) 4 (12.1%)
$20,000–49,999 16 (27.1%) 18 (31.0%) 7 (28%) 11 (33.3%)
$50,000–99,999 23 (39.0%) 19 (32.8%) 6 (24%) 13 (39.4%)
$100,000–149,999 5 (8.5%) 6 (10.3%) 4 (16%) 2 (6.1%)
Chose not to answer 5 (8.5%) 8 (13.8%) 5 (20%) 3 (9.1%)
Employment: Employed/in school 49 (87.5%) 54 (90.0%) 0.67 25 (92.6%) 29 (87.9%) 0.68
Housing: Rent or Own 52 (96.3%) 57 (98.3%) 0.61 25 (96.2%) 32 (100%) 0.45
Insured 47 (81.0%) 58 (95.1%) 0.02 25 (92.6%) 33 (97.1%) 0.58
Current tobacco use 2 (3.4%) 5 (8.3%) 0.44 3 (11.5%) 2 (5.9%) 0.64
BMI* (kg/m2) 25.5 (4.6) 25.4 (4.1) 0.9 24.9 25.8 0.26
IBS diagnosis** 1 (1.7%) 14 (23.3%) <0.01 7 (21.2%) 7 (25.9%) 0.67
Sleep disorder 0 1 (1.6%) 1 0 1 (3.7%) 0.44
Current medications
antiTNF*** 0 42 (71.2%) <0.01 23 (75%) 18 (66.7%) 0.48
Immunomodulators 0 41(68.3%) <0.01 21 (63.6%) 20 (74.1%) 0.39
ASA 0 18 (30.5%) <0.01 11 (34.4%) 7 (25.9%) 0.48
Prednisone 0 3 (5.1%) 0.25 3 (9.4%) 0 0.24
Antidepressant 4 (7.7%) 11 (18.6%) 0.1 9 (28.1%) 2 (7.4%) 0.05
Table 2. Demographic, social and clinical characteristics of CD patients and controls. *BMI: body mass index, 
**IBS: irritable bowel syndrome, ***antiTNF: anti-tumor necrosis factor.
Crohn’s disease 
(n = 61)
Control group 
(n = 60) P
Crohn’s disease, 
remission (n = 27)
Crohn’s disease, 
active (n = 34) P
ESS (>10) 20(33.9%) 17(30.9%) 0.73 5(19.2%) 15(45.5%) 0.03
PSQI (>5) 34(56.7%) 21(35%) 0.02 9(33.3%) 25(75.8%) <0.01
HADS
Anxiety (>8) 25(41.7%) 16(26.7%) 0.08 10(37%) 15(45.5%) 0.51
Depression (>8) 5(8.3%) 4(6.7%) 0.75 2(7.4%) 3(9.1%) 0.75
SIBDQ (≥50) NA NA NA 26(96.3%) 11(33.3%) <0.01
SF36 70.1 79.6 <0.01 77 64.4 <0.01
#bm/day* 2.9 1.3 <0.01 1.8 3.8 <0.01
#bm/night* 0.4 0.1 <0.01 0.1 0.7 0.01
Table 3. Subjective sleep measures and quality of life measures, comparing study groups. *Provided in Table 3 
as included in logistic regression analysis. #bm: number of bowel movements.
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In order to evaluate the relationship between melatonin and sleep in our study population, we utilized medi-
ation analysis. Active CD (compared to controls and patients in remission) is significantly associated with poor 
sleep quality as measured by PSQI, even when adjusting for urine melatonin levels (p = 0.03). Urine melatonin 
had no mediation effect on the causal relationship between disease status and sleep quality (Fig. 2).
Discussion
In this large study, we comprehensively applied a real-time quantitative measurement tool (actigraphy) and vali-
dated sleep questionnaires to define sleep quality in patients with CD in different states of disease activity and as 
compared to healthy controls. This is the first study of its kind with a control population and to include melatonin 
metabolites as a biologic correlate of sleep quality in this population. In composite, CD patients report signifi-
cantly disturbed sleep as compared controls on subjective questionnaires, but this is not confirmed by quantitative 
sleep measurement by actigraphy. Moreover, urine melatonin metabolite levels were also not significantly differ-
ent between groups. These results indicate that daytime sleepiness and poor sleep as reported in IBD patients may 
be driven by factors beyond objectively measured poor sleep.
The perception of disturbed sleep has been evaluated using a variety of survey measures (ESS, PSQI and 
PROMIS). In past studies using these measures, there has been considerable support for disturbed sleep in 
patients with inactive and active disease, when compared to controls2,3,8. Our subjective data builds on previous 
data showing that sleep disturbances exist in CD patients compared to controls and this difference is more pro-
nounced with active CD patients. A survey study utilizing PSQI has shown a correlation of poor sleep to mucosal 
healing in small number of patients, despite clinical remission28. An additional study using electroencephalog-
raphy showed more features of disturbed sleep in 8 pediatric patients with active IBD compared to 14 patients 
with IBD in remission and 24 healthy controls29. Furthermore, elevated inflammatory markers (C-reactive pro-
tein) in the absence of night symptoms were significantly associated with subjectively assessed poor sleep in IBD 
patients30.
Our objective data (actigraphy), however, is counter to what other studies and our hypothesis have suggested. 
A further characterization of sleep disturbance shows that CD patients have significantly more daytime sleepi-
ness. Daytime sleepiness was found to be important in subjective questionnaires, which suggests that patients 
have the strong perception of falling asleep especially during the day. IBD patients commonly also report fatigue 
as a primary concern. Despite the correlation between fatigue and diminished QOL, doctors lack the robust 
knowledge on the pathogenesis of IBD-related fatigue. Fatigue is caused by a complex interaction between med-
ication side effects, poor nutrition, depressive symptoms and inflammation, among others. Other survey-based 
studies have correlated sleep disturbance in IBD patients to fatigue2,31. A systematic approach is required to treat 
fatigue in patients with IBD, which has a sizeable chance of improving QOL for our IBD patients.
We evaluated possible contributors to the difference between subjective and objective sleep measures in 
our study. While our study was not designed to evaluate fatigue, a post-hoc analysis within our SIBDQ ques-
tionnaires revealed that patients with active CD reported fatigue more commonly than patients with disease in 
Predictor Variable OR 95% CI p
Active Crohn’s vs. Crohn’s in remission and controls 3.6 1.1–11.4 0.03
BMI 1.2 1.0–1.3 0.01
Anxiety as measured by HADS 1.3 1.1–1.5 0.001
Urine Melatonin 1.01 1.0–1.02 0.05
Table 4. Predictors of poor sleep as measured by PSQI* among all patients included using multivariable logistic 
regression**. *Poor sleep defined as PSQI > 5. The association of poor sleep by PSQI and the following variables 
were accessed using logistic regression modeling (Crohn’s disease status active vs (control + remission), 
IBS diagnosis, anti-TNFα therapy, antidepressant use, BMI (cont.), HADS_anxiety2(cont.), HADS_
depression2(cont.), SIBDQ(cont.), BowlMovementPerDay(cont.), PatientReportedSleepLatency(cont.), Urine 
Melatonin(cont.).
Crohn’s Disease 
(n = 61)
Control group 
(n = 60) P
Crohn’s disease, 
remission (n = 27)
Crohn’s disease, 
active (n = 34) P-value*
Total sleep time (min) 405.8 415.8 0.15 408 403.9 0.93
Sleep efficiency 91% 91.50% 0.64 92.20% 90.10% 0.19
Latency to persistent sleep (min) 9 9 0.8 8.5 9.5 0.29
Total wake time during sleep (min) 50 48.2 0.53 48.8 50.9 0.5
Numbers of wake episodes 7.8 8.5 0.23 7.3 8.2 0.35
Longest sleep episode duration (min) 209.1 213.1 0.8 222 197.9 0.34
Mean sleep episode duration (min) 91.6 80.3 0.32 103.9 80.8 0.25
Percentage of subjects with normal total sleep time 72.4% 84.20% 0.13 77.80% 67.70% 0.39
Percentage of subjects with normal sleep efficiency 86.4% 85.70% 0.65 92.60% 81.30% 0.19
Percentage of subjects with abnormal wake time during sleep 51.7% 42.90% 0.34 44.40% 57.60% 0.31
Table 5. Actigraphy results, comparing CD severity groups and controls.
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remission (80% of active CD patients have fatigue vs. 44% of patients with inactive CD, Fisher’s exact p = 0.007). 
Independent of quantitatively objective poor sleep, more CD patient’s scores on the ESS measuring daytime sleep-
iness may be driving the patient’s perception of poor sleep (Table 4). While fatigue and daytime sleepiness are 
separate, they may overlap in the same patients with active disease and affect our patients’ survey responses. 
Future work would measure fatigue and evaluate these two important measures and their possible link in CD.
Participants wore an Actigraph (Ambulatory Monitoring, Inc.) on their wrist for one week. Actigraphy is a 
validated technology that has been shown in many situations to be correlated to PSG in determining subjects’ 
sleep duration and awakenings from sleep15. While PSG has advantages over actigraphy in establishing sleep 
Figure 1. Urinary 6-hydroxymelatoin sulfate/creatinine ratio (aMT6:CR ratio) comparing study groups and 
correlation between Harvey Bradshaw Index (HBI) and a Mt6s:Cr ratio.
Figure 2. Mediation effect of Urine melatonin on Crohn’s disease status (active vs (control + remission)) in 
predicting PSQI poor outcome (PSQI_2 > 5) using logistic regression modeling.
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disorders, actigraphy is a good representation of a patient’s sleep over time and allows patients to sleep in their 
normal environment. Nevertheless, actigraphy is dependent on patient adherence. We acknowledge that patients 
could be harboring sleep disorders and certain diagnoses that can only be established via polysomnography, but 
are confident in the advantages of actigraphy including its practical administration override the downfalls for this 
type of real-world observational study as shown in peer-reviewed studies16,17.
Limitations exist in the current literature addressing sleep and IBD health and our study. The majority of 
studies use only subjective self-reported patient questionnaires to assess sleep quality2,5,8. While these subjective 
sleep surveys are validated with objective measures in the general population, only one other study has utilized 
an IBD population or one that includes active disease3. Previous studies using objective sleep assessments such as 
melatonin and polysomnography were performed only in small IBD patient cohorts in remission3,32. The largest 
study to date examining this relationship was part of a larger IBD patient health study and thus had more limited 
assessments of sleep quality8. Another interesting premise is the idea that poor sleep can lead to increased IBD 
activity as suggested by animal models, hence the directionality of the relationship between poor sleep/fatigue 
and active Crohn’s is hard to assess33. Actigraphy has been used in one other large study of CD patients. Qazi et al. 
evaluated 72 patients with CD who were stratified by HBI into remission, mild and moderate-to-severe dis-
ease34. While this study lacked a control population, they found no difference in total sleep time or sleep latency, 
but found that patients with moderate-to-severe disease had reduced sleep efficiency and more minutes awake 
after falling asleep. On multivariate analysis only more minutes awake was significant in the moderate-to-severe 
CD group and controlled substance use (marijuana and opiate) was associated with poor sleep efficiency. A less 
strict set of exclusion criteria including the enrollment of patients on marijuana and opiates may account for the 
observed differences in this study.
We only used self-reported measures of CD disease activity. We acknowledge the limitations of using only 
self-reported survey measures of CD activity as opposed to objective measures such as endoscopy and fecal cal-
protectin and its possible effect on our comparison between active and inactive CD. Furthermore, we included 
11 patients (18.6%) in our Crohn’s group who are on antidepressants as well as 4 patients (7.7%) in the control 
group, given the real-world common use of these medications. Given that this could affect sleep, we adjusted for 
this variable of antidepressant use in our multivariate analysis. Future directions in relation to this work could 
include incorporating specific fatigue measures and questionnaires, attentiveness scales, and using commercially 
available HR monitors that would decrease the cost and difficulty of further study.
Tryptophan metabolism is an important pathway in the pathophysiology of both sleep disturbance and 
depression35. Serotonin and melatonin, neurotransmitters involved in mood and sleep regulation respectively, 
are direct metabolic products of tryptophan along the same pathway. In active Crohn’s disease, tryptophan metab-
olism is instead shunted away from these metabolites along the kynurenine pathway36. In our study, there some-
what unexpectedly a trend toward lower urinary melatonin metabolite levels in controls compared to CD patients 
and no differences in melatonin based on CD activity. As tryptophan metabolism can be modified at many levels, 
compensatory melatonin secretion may help intrinsically correct or treat poor sleep when disease is active. It is 
however noted that the use of the urinary melatonin metabolite and melatonin as a marker of sleep health is lim-
ited by variations due to age, seasons of the year, light exposure duration and intensity, shift work, serious illness, 
and diet, as well as genetic factors37–39.
In conclusion, the perception of sleep disturbance in CD patients is an important health issue that should 
be addressed. Poor sleep and the perception of daytime sleepiness in active CD are not confirmed by objective 
measures (actigraphy) of sleep disturbance in this study cohort. Patient-reported outcomes are at the forefront of 
treatment goals in CD, and further investigation into the reasons self-reported poor sleep in CD is warranted. As 
poor sleep is correlated to fatigue, future studies on the mechanisms of fatigue in CD are also needed due to the 
intriguing relationship between sleep and fatigue.
Data availability
The datasets generated during the current study are available from the corresponding author on reasonable 
request.
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